Trade Names:Vaseretic 5-12.5- Tablets 12.5 mg hydrochlorothiazide, 5 mg enalapril maleate
Trade Names:Vaseretic 10-25- Tablets 25 mg hydrochlorothiazide, 10 mg enalapril maleateVaseretic (Canada)
Enalapril causes vasodilation and decreased BP; hydrochlorothiazide causes loss of body water and increases urine output.
Treatment of hypertension.
Hypersensitivity to any component or to other sulfonamide-derived drugs; history of angioedema related to previous treatment with ACE inhibitor; anuria.
PO 1 to 2 tablets (each containing 10 mg enalapril maleate and 25 mg hydrochlorothiazide) per day.
Store at room temperature in sealed container.
May bind to hydrochlorothiazide and decrease its bioavailability.Diazoxide
Hyperglycemia may occur.Digitalis glycosides
Arrhythmias may occur.Indomethacin
Hypotensive effects may be reduced.Lithium
Toxicity risk is greater; avoid use.Loop diuretics
Synergistic effects may cause profound diuresis and electrolyte abnormalities.Potassium preparations, potassium-sparing diuretics
May increase serum potassium levels.Sulfonylureas
May require dose adjustment.
PBI levels may be decreased without signs of thyroid disturbances; diagnostic interference with serum electrolyte levels, blood and urinary glucose levels, serum bilirubin levels and serum uric acid levels.
Hypotension; orthostatic effects; palpitations; tachycardia; chest pain.
Dizziness; headache; insomnia; nervousness; paresthesia; somnolence; vertigo; syncope.
Tinnitus; dry mouth.
Nausea; diarrhea; abdominal pain; vomiting; dyspepsia; constipation; flatulence.
Impotence; decreased libido; urinary tract infections.
Hyperkalemia; hyponatremia; hypercalcemia; hypochloremic alkalosis; hypokalemia; gout; hypomagnesemia; hyperglycemia; increased triglyceride and cholesterol levels.
Chronic cough; dyspnea.
Angioedema; fatigue; weakness; muscle cramps; back pain; sweating.
When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, discontinue therapy as soon as possible.
Category D (second, third trimester); Category C (first trimester).
Excreted in breast milk.
Safety and efficacy not established.
Use drug with caution in patients with renal disease and monitor renal function periodically; may precipitate azotemia; may alter renal function in susceptible individuals (including those with severe CHF). Use drug with caution in patients with impaired hepatic function or progressive liver disease, because changes in fluid and electrolyte balance can precipitate hepatic coma.
Angioedema of face, extremities, lips, tongue, glottis, or larynx has been reported in patients treated with enalapril. Discontinue drug.
Other ACE inhibitors have caused bone marrow depression, particularly in patients with renal function impairment and collagen vascular disease. Monitor hematopoietic system.
Monitor closely, because adjustments may be needed in hypoglycemic agents.
May be activated or exacerbated.
Hypotension, orthostatic hypotension, dizziness, drowsiness, syncope, electrolyte abnormalities, hemoconcentration, confusion, muscular weakness, nausea, vomiting, depressed respiration, lethargy, coma.
Copyright © 2009 Wolters Kluwer Health.